VM:CC - Voyageur Pharmaceuticals and API Forge Alliance for Carbon-Based Imaging Drug Advancement

(TheNewswire)

Calgary, Canada – TheNewswire - March 4, 2024 - Voyageur Pharmaceuticals Ltd . (TSX.V: VM) (USA: VYYRF) ("Voyageur" or the"Corporation") and Applied Pharmaceutical Innovation (API), aleading industry-funded not-for-profit organization driving lifesciences commercialization, proudly announce the signing of a MasterServices Agreement ( MSA ). This collaboration represents asignificant advancement in both entities’ commitment to innovation,heralding a transformative step forward for Canada’s thriving lifesciences sector.

Under this strategic agreement, API will play a crucialrole in accelerating Voyageur’s imaging contrast medium productdevelopment, manufacturing, and commercialization. Leveraging API’sscientific and pharmaceutical expertise, the collaboration aims tofacilitate regulatory approvals and expedite the market entry ofVoyageur’s contrast imaging products.

This partnership will strategically target FDA, HealthCanada and other regulatory agencies, by licensing across several keydevelopment areas:

• Accelerating the development andregistration of the innovative V@C60 MRI drug (Vanadium Fullerene Molecule for magnetic resonance imaging https://voyageurpharmaceuticals.ca/voyageur-pharmaceuticals-ltd-and-rain-cage-carbon-inc-announce-breakthrough-in-imaging-technology-with-vanadium-fullerene-molecule/

• Developing novel fullerene imagingproducts for targeted drug delivery within the body, with a focus onapplications in Oncology.

• Introducing an advanced suite of newbarium contrast media products, with the goal to displace currentproducts in the market.

• Expanding Voyageur’s Iodinecontrast media product pipeline, including potential development offullerene iodine products

• Developing a carbon 60 basednutraceutical health supplement

"We are thrilled to embark on this groundbreakingcollaboration with Voyageur, advancing healthcare through thecommercialization of mineral-based active pharmaceutical ingredientsfor the medical imaging market," stated Andrew MacIsaac, CEO atAPI. "This partnership underscores our commitment to drivinginnovation and elevating the life sciences landscape in Canada andglobally."

Brent Willis, CEO of Voyageur, expressed excitementabout the collaboration, stating, "Our vision is to become theworld's first company capable of creating new carbon-based drugs fromcaptured CO 2 , ensuringcarbon-neutral pharmaceuticals. This strategic alliance with API willaccelerate Voyageur's development programs, with a primary focus oncreating a groundbreaking carbon-based MRI drug and advancing ouriodine contrast media product pipeline."

By amalgamating API's regulatory expertise withVoyageur's research and development capabilities, this partnership ispoised to showcase global leadership in pharmaceutical development.The collaboration exemplifies how the intersection of Alberta'sstrengths in natural resources, scientific innovation, andenvironmental stewardship can result in enhanced healthcare solutionsworldwide. Together, API and Voyageur aim to streamline theintegration of Voyageur’s contrast media products, reducing supplychain risks and aiding healthcare practitioners in diagnosingdiseases, disorders, and abnormalities globally.

About Voyageur PharmaceuticalsLtd.:

Voyageur (TSX Venture Exchange: VM) is a Canadianpublic company at the forefront of barium, iodine, and carbon ActivePharmaceutical Ingredients (API) and high-performance, cost-effectiveimaging contrast agents. Focused on vertically integrating the barium,iodine, and carbon contrast imaging market, Voyageur aims to become akey player by producing its own minerals.

Committed to sustainability, Voyageur envisions afuture of carbon neutrality. Utilising Rain Cage Carbon Inc patentedEden System, Voyageur plans to capture carbon producing an addedrevenue stream to help finance operations and create the carbon usedfor new drug development. The Corporation holds a 100% interest in theFrances Creek property, a NI-43-101 barium sulfate (barite) projectwith an assigned $344M NPV based on a 2021 preliminary economicassessment. Voyageur is building vertical integrated product linesthat are all 100% carbon neutral.

About API:

API stands as one of Canada's largest life sciencescommercialization organizations, dedicated to enhancing thequality-of-life sciences. As an industry-funded not-for-profit, APIprovides end-to-end support to life sciences researchers, businesses,and innovators on their journey from idea to commercialization. Withscientific leadership from Nobel Laureate Sir Michael Houghton, APIprovides access to facilities and experts that help pharmaceuticalprojects reach the market. With a commitment to sharing expertise,resources, and infrastructure, API aims to build an unparalleled lifesciences sector driving prosperity for all.

For media inquiries, please contact:

Voyageur Pharmaceuticals Ltd.

API (Applied PharmaceuticalInnovation)

Tessa Vriend, Director, Engagement & Brand

tessa.vriend@appliedpharma.ca

Neither the TSX Venture Exchange nor its RegulationServices Provider (as that term is defined in the policies of the TSXVenture Exchange) accepts responsibility for the adequacy or accuracyof this news release.

Cautionary Statement Regarding “Forward-Looking”Information.

This news release may contain certain forward-lookinginformation and statements, including without limitation, statementspertaining to the perceived benefits to Voyageur from entering intothe MSA; Voyageur’s expectations and timing with respect todeveloping pharmaceutical drugs including the Va@C60 MRI drug,fullerene imaging drugs, new barium contrast drugs, iodine contrastand fullerene iodine drugs, and nutraceutical health supplements;Voyageur’s perceived costs and other benefits from its collaborationwith API; Voyageur’s anticipated plans and benefits from itsrelationship with API; Voyageur’s expectation that it will be ableto secure the financing necessary to pursue its objectives; and otherstatements herein, which expressly or impliedly speak to Voyageur’sexpectations for its business and operations.  All statementsincluded herein, other than statements of historical fact, areforward-looking information and such information involves variousrisks and uncertainties, including, without limitation, global marketfactors and supply chain issues, risks relating to the regulation andapproval of Voyageur’s products, and general risks relating toVoyageur’s business.  There can be no assurance that suchinformation will prove to be accurate and actual.

Copyright (c) 2024 TheNewswire - All rights reserved.